CC
TXG icon

Casdin Capital’s 10x Genomics TXG Stock Holding History

Casdin Capital’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$40.3M Sell
1,050,000
-1,225,000
-54% -$32.1M 2.02% 11
2026
Q1 		$48.3M Buy
2,275,000
+875,000
+63% +$17.5M 3.66% 8
2025
Q4 		$22.8M Buy
+1,400,000
New +$21.1M 1.42% 15

Other funds holding TXG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
QCM
Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Casdin Capital's TXG Position: Q2 2026 in Review

Casdin Capital reduced its 10x Genomics (TXG) stake by 54% in Q2 2026, selling an estimated $32.1M and leaving 1,050,000 shares worth $40.3M. The position accounts for 2.02% of the portfolio, ranked #11.

Casdin Capital first reported a position in TXG in Q4 2025 and has held it in 3 quarters since. The position peaked at $48.3M in Q1 2026. 391 funds tracked by Wall St. Rank hold TXG as of Q2 2026.

  • Casdin Capital held 1,050,000 shares of 10x Genomics worth $40.3M as of Q2 2026.
  • Casdin Capital sold 1,225,000 10x Genomics shares in Q2 2026, an estimated $32.1M.
  • 10x Genomics made up 2.02% of Casdin Capital's portfolio in Q2 2026, its #11 holding.
  • Casdin Capital first reported a position in 10x Genomics in Q4 2025 and has held it in 3 quarters since.
  • Casdin Capital's 10x Genomics position peaked at $48.3M in Q1 2026.
  • 391 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2026.

Based on Casdin Capital's 13F filing for Q2 2026, filed 14 Aug 2026.